Home / Deep Research / PIK3CA-Mutant Breast Cancer

PIK3CA-Mutant Breast Cancer

Disease Pathophysiology Research Report

2026-01-24
Falcon MONDO:0004989 Model: Edison Scientific Literature 14 citations

Disease Pathophysiology Research Report

Target Disease - Disease Name: PIK3CA‑Mutant Breast Cancer - MONDO ID: MONDO:0007254 (breast carcinoma; PIK3CA‑mutant subtype within HR+/HER2− predominates) - Category: Neoplasm; epithelial carcinoma

Pathophysiology description (narrative) PIK3CA encodes the p110α catalytic subunit of class IA PI3K. Oncogenic hotspot mutations cluster in the helical domain (E542K, E545K) and kinase domain (H1047R). These mutations increase conversion of PI(4,5)P2 to PIP3, leading to AKT and mTORC1/2 activation and broad transcriptional and metabolic reprogramming that supports proliferation and survival in breast cancer, especially HR+/HER2− disease where prevalence approaches ~35–40% in large series. Recent profiling across >50,000 breast tumors confirms PIK3CA as the most frequently altered PI3K‑pathway gene and details the dominance of H1047R/E545K/E542K hotspots. (tao2025clinicogenomiclandscapeand pages 1-4) Mechanistically, mutant p110α shows conformational and allosteric changes that favor the active state and enhance membrane engagement and signaling output. Orthosteric PI3Kα inhibitors suppress both mutant and wild‑type PI3Kα and cause on‑target metabolic toxicity; accordingly, mutant‑selective allosteric inhibitors (e.g., RLY‑2608) have been designed to “decouple antitumor activity from hyperinsulinemia,” with early clinical responses reported. Structural and translational work supports mutant‑selective binding pockets and allosteric control as a path to improved therapeutic index. (varkaris2024discoveryandclinical pages 1-3) Functional proteomic studies in real‑world metastatic breast cancer (MBC) cohorts demonstrate that genomic alterations incompletely predict pathway activity; many genomically wild‑type tumors exhibit AKT phosphorylation comparable to mutant tumors, and high p70S6K phosphorylation correlates with inferior PFS on CDK4/6 inhibitor plus endocrine therapy, underscoring the importance of measuring pathway activation alongside genomics. (prasad2024functionalactivationof pages 1-2)

  1. Core Pathophysiology
  2. Primary mechanisms activating PI3Kα:
  3. Helical domain mutations (E542K/E545K) disrupt inhibitory contacts with the p85 regulatory subunit and facilitate RAS‑effector and membrane interactions, increasing basal lipid kinase activity; kinase domain mutation H1047R remodels the C‑terminal region to promote membrane binding and catalysis. Contemporary structural/pharmacologic studies emphasize mutation‑specific allosteric networks in PI3Kα. (varkaris2024discoveryandclinical pages 1-3)
  4. Dysregulated signaling pathways:
  5. PI3K→PIP3→AKT→mTORC1/2 axis drives protein synthesis, survival, growth, and metabolism; pathway activation is frequent in HR+/HER2− MBC and can be captured by phosphoprotein markers such as pAKT and p70S6K. (prasad2024functionalactivationof pages 1-2, tao2025clinicogenomiclandscapeand pages 1-4)
  6. Cellular processes affected:

  7. Increased proliferation/cell‑cycle progression, survival under endocrine pressure, metabolic rewiring (glucose/insulin signaling feedback), and likely EMT/invasion in specific contexts; codon‑level variation tracks with metastatic tropism (e.g., PIK3CA 1047/542 associated with bone metastases in luminal MBC). (gerratana2023interplaybetweenesr1pik3ca pages 1-2, prasad2024functionalactivationof pages 1-2)

  8. Key Molecular Players

  9. Genes/Proteins (HGNC):
  10. PIK3CA (HGNC:8975; p110α catalytic subunit), PIK3R1 (HGNC:8979; p85 regulatory subunit), AKT1 (HGNC:391), MTOR (HGNC:3942), PTEN (HGNC:9588), ESR1 (HGNC:3467). (tao2025clinicogenomiclandscapeand pages 1-4, prasad2024functionalactivationof pages 1-2, gerratana2023interplaybetweenesr1pik3ca pages 1-2)
  11. Chemical Entities (examples; CHEBI where applicable):
  12. PI(4,5)P2 and PIP3 lipids (CHEBI:18348; CHEBI:16618) as substrates/products of PI3Kα; approved/late‑phase drugs include alpelisib (PI3Kα inhibitor), capivasertib (AKT inhibitor), and inavolisib (mutant‑active PI3Kα inhibitor with mutant p110α degradation). RLY‑2608 is a mutant‑selective allosteric PI3Kα inhibitor in clinical development. (prasad2024functionalactivationof pages 1-2, turner2024inavolisibbasedtherapyin pages 1-2, varkaris2024discoveryandclinical pages 1-3)
  13. Cell Types (CL):
  14. Luminal mammary epithelial tumor cells (CL:0002328) and tumor microenvironment components (cancer‑associated fibroblasts, macrophages) that feedback into PI3K/insulin and growth‑factor signaling; codon‑level variants associate with specific dissemination patterns within luminal MBC. (gerratana2023interplaybetweenesr1pik3ca pages 1-2)
  15. Anatomical Locations (UBERON):

  16. Primary: Breast/mammary gland epithelium (UBERON:0001911, UBERON:0008290). Common metastatic sites for HR+ PIK3CA‑mutant disease include bone and liver; bone enrichment is noted for specific codon classes. (gerratana2023interplaybetweenesr1pik3ca pages 1-2)

  17. Biological Processes (GO terms; disrupted)

  18. GO:0014065 phosphatidylinositol 3‑kinase signaling; GO:0035556 intracellular signal transduction; GO:1900740 positive regulation of protein kinase B signaling; GO:0008284 positive regulation of cell proliferation; GO:0009267 cellular response to starvation; GO:0001932 regulation of protein phosphorylation; GO:0046328 regulation of JAK‑STAT/insulin signaling crosstalk (as pathway cross‑talk); GO:0001837 epithelial to mesenchymal transition (context‑specific). Evidence: pathway activation and clinical responses to PI3K/AKT targeting; phosphoprotein correlates; codon‑specific clinical phenotypes. (prasad2024functionalactivationof pages 1-2, tao2025clinicogenomiclandscapeand pages 1-4, gerratana2023interplaybetweenesr1pik3ca pages 1-2)

  19. Cellular Components (GO CC)

  20. Plasma membrane signaling complexes (PI3Kα at inner leaflet), cytosol (AKT), mTORC1 (lysosome) and mTORC2 (membrane‑associated), and lipid microdomains where PI(4,5)P2→PIP3 conversion occurs. Structural data highlight mutation‑specific conformations that alter membrane engagement/allosteric pockets in PI3Kα. (varkaris2024discoveryandclinical pages 1-3)

  21. Disease Progression (sequence of events)

  22. Initial trigger: Acquisition of PIK3CA hotspot mutation (often early in luminal tumorigenesis) creates constitutive PI3K lipid kinase activity.
  23. Early consequences: Elevated PIP3 recruits/activates AKT and downstream mTOR, increasing protein synthesis and survival under endocrine pressure; ER pathway crosstalk sustains proliferation. (tao2025clinicogenomiclandscapeand pages 1-4, prasad2024functionalactivationof pages 1-2)
  24. Progression: Additional alterations (e.g., ESR1 mutations, PTEN loss) and adaptive feedback (hyperinsulinemia with PI3Kα inhibition) drive resistance and metastatic spread; codon‑variant patterns associate with bone metastasis and differential co‑alterations. (gerratana2023interplaybetweenesr1pik3ca pages 1-2, prasad2024functionalactivationof pages 1-2)

  25. Clinical manifestation: Endocrine‑resistant HR+ MBC with measurable dependence on PI3K/AKT/mTOR signaling by genomics and/or phosphoproteomics. (prasad2024functionalactivationof pages 1-2)

  26. Phenotypic Manifestations (HP terms; examples)

  27. Cancer of breast (HP term association), metastatic bone disease with pain/pathologic fractures; endocrine resistance and progression while on AI±CDK4/6i; treatment‑emergent metabolic adverse events with PI3Kα inhibitors (e.g., hyperglycemia/insulin resistance). (turner2024inavolisibbasedtherapyin pages 1-2, prasad2024functionalactivationof pages 1-2)

Recent developments and latest research (2023–2024 prioritized) - Mutant‑selective allosteric PI3Kα inhibition (RLY‑2608): First‑in‑class approach shows preclinical breadth across helical and kinase domain mutants and initial clinical responses with reduced metabolic toxicity, providing a platform for overcoming limitations of orthosteric PI3Kα inhibitors. (Cancer Discovery; DOI:10.1158/2159-8290.CD-23-0944; published Nov 2024; URL: https://doi.org/10.1158/2159-8290.cd-23-0944). (varkaris2024discoveryandclinical pages 1-3) - Functional activation vs genomics: Real‑world phosphoprotein profiling demonstrates poor concordance of mutations with pathway activity and prognostic value of p70S6K phosphorylation under CDK4/6+ET, supporting biomarker strategies that combine phospho‑signaling with genomics. (Br J Cancer; DOI:10.1038/s41416-024-02852-y; online Sep 25, 2024; URL: https://doi.org/10.1038/s41416-024-02852-y). (prasad2024functionalactivationof pages 1-2) - Codon‑level ESR1/PIK3CA interplay in luminal MBC: Large ctDNA NGS series reveals variant‑specific co‑alteration patterns and metastatic tropism (e.g., PIK3CA 1047/542 with bone metastases), emphasizing precision beyond “mutant vs wild‑type.” (Breast Cancer Research; DOI:10.1186/s13058-023-01718-0; Oct 2023; URL: https://doi.org/10.1186/s13058-023-01718-0). (gerratana2023interplaybetweenesr1pik3ca pages 1-2)

Current applications and real‑world implementations - Alpelisib (PI3Kα inhibitor) is an established therapy for HR+/HER2−, PIK3CA‑mutated MBC, but toxicity (notably hyperglycemia) limits use. Contemporary real‑world and translational analyses support that pathway activation and benefit may extend beyond strict genomic selection, advocating combined genomic and phospho‑signaling assessment in practice. (prasad2024functionalactivationof pages 1-2) - Capivasertib (AKT inhibitor) plus fulvestrant: Based on CAPItello‑291 (NEJM 2023), gained approval for HR+/HER2− advanced breast cancer with PIK3CA/AKT1/PTEN alterations; pathway‑altered subgroup doubled median PFS vs placebo+fulvestrant (7.3 vs 3.1 months) and overall cohort also benefited, providing a genomically anchored, endocrine‑based regimen post‑AI±CDK4/6i. (statistics as reported in contemporary clinicogenomic review; medRxiv 2025 summarizing NEJM 2023; URL: https://doi.org/10.1101/2025.06.18.25329632). (tao2025clinicogenomiclandscapeand pages 1-4) - Inavolisib (selective PI3Kα inhibitor with mutant p110α degradation) plus palbociclib‑fulvestrant (first‑line, INAVO120, NEJM 2024): Median PFS 15.0 vs 7.3 months (HR 0.43; P<0.001); ORR 58.4% vs 25.0%. Hyperglycemia and stomatitis increased but discontinuation remained low (6.8%). This validates intensified, mechanism‑guided triplet targeting ER/CDK4‑6/PI3Kα in PIK3CA‑mutant disease. (DOI:10.1056/NEJMoa2404625; Oct 2024; URL: https://doi.org/10.1056/nejmoa2404625). (turner2024inavolisibbasedtherapyin pages 1-2)

Expert opinions and analysis from authoritative sources - Translational and structural experts propose that mutation‑specific allosteric pockets in PI3Kα enable selective inhibition that preserves insulin signaling homeostasis, addressing a central liability of orthosteric PI3Kα inhibitors. Early clinical results with RLY‑2608 substantiate this concept. (varkaris2024discoveryandclinical pages 1-3) - Precision oncology implementation should integrate pathway phosphoprotein readouts with genomics to identify PI3K/AKT/mTOR‑driven tumors and guide sequencing with ET, CDK4/6i, PI3Kα/AKT/mTOR inhibitors post‑CDK4/6i progression. (prasad2024functionalactivationof pages 1-2)

Relevant statistics and data from recent studies - Prevalence and hotspot spectrum: In a clinicogenomic dataset of 51,767 breast tumors, PIK3CA altered in 37.4%; hotspot distribution among PIK3CA mutations: H1047R 35.6%, E545K 19.7%, E542K 11.7%. (medRxiv; Jun 18, 2025; URL: https://doi.org/10.1101/2025.06.18.25329632). (tao2025clinicogenomiclandscapeand pages 1-4) - Capivasertib+fulvestrant: Median PFS 7.3 vs 3.1 months in AKT‑pathway‑altered tumors (CAPItello‑291 summary), regulatory approval subsequently granted for HR+/HER2− ABC with PIK3CA/AKT1/PTEN alterations. (tao2025clinicogenomiclandscapeand pages 1-4, prasad2024functionalactivationof pages 1-2) - Inavolisib+palbociclib‑fulvestrant (INAVO120): Median PFS 15.0 vs 7.3 months (HR 0.43); ORR 58.4% vs 25.0%; low discontinuation despite increased grade ≥3 AEs; NEJM 2024. (turner2024inavolisibbasedtherapyin pages 1-2) - Phosphoproteomics in real‑world MBC: Genomics poorly predicted protein activation (AUC 0.69); AKT phosphorylation mirrored mutant signaling in 76.9% of genomically wild‑type tumors; high p70S6K(T389) associated with shorter PFS on CDK4/6+ET (HR 4.18). (prasad2024functionalactivationof pages 1-2) - Codon‑specific clinical patterns: PIK3CA 1047 and 542 variants associated with bone metastases in ctDNA‑profiled luminal MBC; ESR1 codon variants show distinct co‑alterations and metastatic patterns. (gerratana2023interplaybetweenesr1pik3ca pages 1-2)

Gene/protein annotations with ontology terms (examples) - PIK3CA (HGNC:8975): GO BP—phosphatidylinositol 3‑kinase signaling, positive regulation of AKT signaling; GO CC—plasma membrane, cytosol; GO MF—phosphatidylinositol 3‑kinase activity. (varkaris2024discoveryandclinical pages 1-3, prasad2024functionalactivationof pages 1-2) - AKT1 (HGNC:391): GO BP—cell proliferation, apoptosis regulation; GO CC—cytosol, plasma membrane; GO MF—protein serine/threonine kinase activity. (prasad2024functionalactivationof pages 1-2) - MTOR (HGNC:3942): GO BP—mTOR signaling, translation regulation; GO CC—lysosome (mTORC1), cytosol/membrane (mTORC2). (prasad2024functionalactivationof pages 1-2) - PTEN (HGNC:9588): GO BP—negative regulation of PI3K signaling via PIP3 dephosphorylation; GO MF—phosphatidylinositol‑3,4,5‑trisphosphate 3‑phosphatase activity. (tao2025clinicogenomiclandscapeand pages 1-4) - ESR1 (HGNC:3467): GO BP—hormone‑mediated signaling, transcription regulation; crosstalk with PI3K/AKT underlies endocrine resistance. (gerratana2023interplaybetweenesr1pik3ca pages 1-2, prasad2024functionalactivationof pages 1-2)

Phenotype associations (HP terms; examples) - Endocrine therapy resistance in HR+ MBC; metastatic bone disease; treatment‑emergent hyperglycemia with PI3Kα inhibitors. (turner2024inavolisibbasedtherapyin pages 1-2, prasad2024functionalactivationof pages 1-2)

Cell type involvement (CL terms) - Luminal mammary epithelial tumor cells (CL:0002328) as primary drivers; tumor stroma and immune cells modulate growth‑factor/insulin signaling, reinforcing PI3K pathway. (prasad2024functionalactivationof pages 1-2, gerratana2023interplaybetweenesr1pik3ca pages 1-2)

Anatomical locations (UBERON terms) - Breast/mammary gland epithelium (UBERON:0001911, UBERON:0008290); bone and liver as common sites of metastatic involvement in luminal MBC, with codon‑specific associations. (gerratana2023interplaybetweenesr1pik3ca pages 1-2)

Chemical entities (CHEBI terms; examples) - PI(4,5)P2 (CHEBI:18348), PIP3 (CHEBI:16618); pharmacologic agents: alpelisib, inavolisib, capivasertib, and experimental RLY‑2608 (mutant‑selective allosteric PI3Kα inhibitor). (prasad2024functionalactivationof pages 1-2, turner2024inavolisibbasedtherapyin pages 1-2, varkaris2024discoveryandclinical pages 1-3)

Evidence items with URLs and publication dates - Varkaris A et al. Discovery and clinical proof‑of‑concept of RLY‑2608… Cancer Discovery. Published Nov 2024. DOI:10.1158/2159-8290.CD-23-0944. URL: https://doi.org/10.1158/2159-8290.cd-23-0944 (mutant‑selective PI3Kα, structural/allosteric insights, early clinical activity). (varkaris2024discoveryandclinical pages 1-3) - Turner NC et al. Inavolisib‑Based Therapy in PIK3CA‑Mutated Advanced Breast Cancer. NEJM. Oct 2024; 391:1584‑1596. DOI:10.1056/NEJMoa2404625. URL: https://doi.org/10.1056/nejmoa2404625 (phase 3 PFS/ORR, toxicity profile). (turner2024inavolisibbasedtherapyin pages 1-2) - Prasad D et al. Functional activation of the AKT‑mTOR signalling axis… Br J Cancer. Online Sep 25, 2024. DOI:10.1038/s41416-024-02852-y. URL: https://doi.org/10.1038/s41416-024-02852-y (genomics vs phospho‑signaling, prognostic p70S6K). (prasad2024functionalactivationof pages 1-2) - Gerratana L et al. Interplay between ESR1/PIK3CA codon variants… Breast Cancer Research. Oct 2023. DOI:10.1186/s13058-023-01718-0. URL: https://doi.org/10.1186/s13058-023-01718-0 (codon‑specific co‑alterations, metastatic patterns, ctDNA utility). (gerratana2023interplaybetweenesr1pik3ca pages 1-2) - Tao JJ et al. Clinicogenomic landscape and function of PIK3CA, AKT1, and PTEN mutations in breast cancer. medRxiv. Jun 18, 2025. DOI:10.1101/2025.06.18.25329632. URL: https://doi.org/10.1101/2025.06.18.25329632 (prevalence, hotspot distribution, clinical targeting; summarizes CAPItello‑291 findings). (tao2025clinicogenomiclandscapeand pages 1-4)

Direct quotes supporting key statements - “In patients with PIK3CA‑mutated, hormone receptor‑positive, HER2‑negative locally advanced or metastatic breast cancer, inavolisib plus palbociclib‑fulvestrant led to significantly longer progression‑free survival than placebo plus palbociclib‑fulvestrant” (NEJM 2024). (turner2024inavolisibbasedtherapyin pages 1-2) - RLY‑2608 “decouples antitumor activity from hyperinsulinemia” via mutant‑selective allosteric inhibition (Cancer Discovery 2024). (varkaris2024discoveryandclinical pages 1-3) - “Genomic profiles emerged as poor predictors of protein activity (AUC: 0.69)… AKT phosphorylation levels mimicked those of mutant lesions in 76.9% of wild‑type tumours” (Br J Cancer 2024). (prasad2024functionalactivationof pages 1-2)

Clinical testing and liquid biopsy - ctDNA NGS enables codon‑level profiling of ESR1/PIK3CA and pathway co‑alterations that inform treatment selection and predict metastatic patterns; real‑world data advocate combining genomic panels with phosphoprotein markers to refine selection for PI3K/AKT‑pathway inhibitors. (gerratana2023interplaybetweenesr1pik3ca pages 1-2, prasad2024functionalactivationof pages 1-2)

Conclusions PIK3CA‑mutant breast cancer is driven by mutation‑specific activation of PI3Kα that amplifies AKT/mTOR signaling, fosters endocrine resistance, and shapes metastatic behavior. 2023–2024 data establish effective, biomarker‑guided targeting via AKT inhibition (capivasertib+fulvestrant) and next‑generation PI3Kα approaches (inavolisib triplet; mutant‑selective allosteric inhibition with RLY‑2608). Implementation should integrate genomics with phospho‑signaling to accurately identify pathway‑addicted tumors and optimize sequencing with ET and CDK4/6 inhibitors. (tao2025clinicogenomiclandscapeand pages 1-4, turner2024inavolisibbasedtherapyin pages 1-2, varkaris2024discoveryandclinical pages 1-3, prasad2024functionalactivationof pages 1-2, gerratana2023interplaybetweenesr1pik3ca pages 1-2)

References

  1. (varkaris2024discoveryandclinical pages 1-3): Andreas Varkaris, Ermira Pazolli, Hakan Gunaydin, Qi Wang, Levi Pierce, Alessandro A. Boezio, Artemisa Bulku, Lucian DiPietro, Cary Fridrich, Adam Frost, Fabrizio Giordanetto, Erika P. Hamilton, Katherine Harris, Michael Holliday, Tamieka L. Hunter, Amanda Iskandar, Yongli Ji, Alexandre Larivée, Jonathan R. LaRochelle, André Lescarbeau, Fabien Llambi, Brenda Lormil, Mary M. Mader, Brenton G. Mar, Iain Martin, Thomas H. McLean, Klaus Michelsen, Yakov Pechersky, Erika Puente-Poushnejad, Kevin Raynor, Dipali Rogala, Ramin Samadani, Alison M. Schram, Kelley Shortsleeves, Sweta Swaminathan, Shahein Tajmir, Gege Tan, Yong Tang, Roberto Valverde, Bryan Wehrenberg, Jeremy Wilbur, Bret R. Williams, Hongtao Zeng, Hanmo Zhang, W. Patrick Walters, Beni B. Wolf, David E. Shaw, Donald A. Bergstrom, James Watters, James S. Fraser, Pascal D. Fortin, and D. Randal Kipp. Discovery and clinical proof-of-concept of rly-2608, a first-in-class mutant-selective allosteric pi3kα inhibitor that decouples antitumor activity from hyperinsulinemia. Cancer Discovery, 14:240-257, Nov 2024. URL: https://doi.org/10.1158/2159-8290.cd-23-0944, doi:10.1158/2159-8290.cd-23-0944. This article has 86 citations and is from a highest quality peer-reviewed journal.

  2. (turner2024inavolisibbasedtherapyin pages 1-2): Nicholas C. Turner, Seock-Ah Im, Cristina Saura, Dejan Juric, Sibylle Loibl, Kevin Kalinsky, Peter Schmid, Sherene Loi, Patrapim Sunpaweravong, Antonino Musolino, Huiping Li, Qingyuan Zhang, Zbigniew Nowecki, Roland Leung, Eirini Thanopoulou, Noopur Shankar, Guiyuan Lei, Thomas J. Stout, Katherine E. Hutchinson, Jennifer L. Schutzman, Chunyan Song, and Komal L. Jhaveri. Inavolisib-based therapy in pik3ca-mutated advanced breast cancer. The New England journal of medicine, 391 17:1584-1596, Oct 2024. URL: https://doi.org/10.1056/nejmoa2404625, doi:10.1056/nejmoa2404625. This article has 215 citations and is from a highest quality peer-reviewed journal.

  3. (prasad2024functionalactivationof pages 1-2): Deepika Prasad, Elisa Baldelli, Edik M. Blais, Justin Davis, Emna El Gazzah, Claudius Mueller, Alison Gomeiz, Aisha Ibrahim, Avani Vinayak Newrekar, Brian A. Corgiat, Rick Dunetz, Emanuel F. Petricoin III, Qi Wei, and Mariaelena Pierobon. Functional activation of the akt-mtor signalling axis in a real-world metastatic breast cancer cohort. British Journal of Cancer, 131:1543-1554, Sep 2024. URL: https://doi.org/10.1038/s41416-024-02852-y, doi:10.1038/s41416-024-02852-y. This article has 7 citations and is from a domain leading peer-reviewed journal.

  4. (gerratana2023interplaybetweenesr1pik3ca pages 1-2): Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, Katherine Clifton, Whitney L. Hensing, Ami N. Shah, Charles S. Dai, Carolina Reduzzi, Paolo D’Amico, Firas Wehbe, Arielle Medford, Seth A. Wander, William J. Gradishar, Amir Behdad, Fabio Puglisi, Cynthia X. Ma, Aditya Bardia, and Massimo Cristofanilli. Interplay between esr1/pik3ca codon variants, oncogenic pathway alterations and clinical phenotype in patients with metastatic breast cancer (mbc): comprehensive circulating tumor dna (ctdna) analysis. Breast Cancer Research : BCR, Oct 2023. URL: https://doi.org/10.1186/s13058-023-01718-0, doi:10.1186/s13058-023-01718-0. This article has 10 citations.

  5. (tao2025clinicogenomiclandscapeand pages 1-4): Jacqueline J. Tao, Saumya D. Sisoudiya, Hanna Tukachinsky, Alexa Schrock, Smruthy Sivakumar, Ethan S. Sokol, and Neil Vasan. Clinicogenomic landscape and function of pik3ca, akt1, and pten mutations in breast cancer. medRxiv : the preprint server for health sciences, Jun 2025. URL: https://doi.org/10.1101/2025.06.18.25329632, doi:10.1101/2025.06.18.25329632. This article has 0 citations.